Presbyopia - Market Insights, Epidemiology, and Market Forecast—2030
- January 2021 •
- 97 pages •
- Report ID: 6025274 •
- Format: PDF
‘Presbyopia - Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States.
The Presbyopia market report provides current treatment practices, emerging drugs, Presbyopia market share of the individual therapies, current and forecasted Presbyopia market size from 2018 to 2030 segmented by the United States. The Report also covers current Presbyopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
• The United States
Study Period: 2018–2030
Presbyopia: Disease Understanding and Treatment Algorithm
Presbyopia, a natural age-related condition, is the result of a gradual decrease in accommodative amplitude, from about 15 diopters (D) in early childhood to 1 D before the age of 60 years. An irreversible, normal physiologic condition that affects all primates, it impairs the ability to see clearly at near. It is a natural part of aging. Presbyopia usually becomes noticeable in the early to mid-40s and continues to worsen until around age 65.
Presbyopia is partly due to age-related changes in the proteins within the lens of the eye that cause it to become thicker, harder, and less flexible. This loss of flexibility affects the lens’s ability to refract light rays which, in turn, affects the eye’s capacity to focus. Age-related changes also occur in the muscle fibers surrounding the lens that aid in focus, further aggravating the problem.
Initial symptoms may be difficulties with prolonged close-up work, with tiring (eye strain) of the eyes; this may be worse in dim light. People may also notice difficulty in adjusting vision if they glance from a near object to a faraway one. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.
Presbyopia can be diagnosed by an optometrist, ophthalmologist, or physician, who takes a complete medical history to determine the extent of the vision problem. The doctor also tests the vision by having the patient read the text at a typically comfortable distance. If the diagnoses of presbyopia are confirmed, the doctor may perform a test to determine the extent of the focusing problem and the appropriate lens prescription. In this test, the doctor asks the patient to look through corrective lenses and continues to increase the magnification power until the words on the page are clear and comfortable enough to be read by the patient. A thorough assessment of the health of the eyes and associated structures is an integral component of the comprehensive adult eye and vision examination. This examination can lead to the diagnosis of systemic diseases and disorders that have ocular manifestations
A variety of options are available for optical correction of presbyopia, and the optometrist makes recommendations on the basis of the patient’s specific vocational and avocational needs. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.
Several types of surgery are available and new techniques and technologies are making them safer and more effective. Refractive surgical procedures include Conductive Keratoplasty, LASIK, LASEK, and Photorefractive Keratectomy.
The Presbyopia epidemiology division provides insights about the historical and current Presbyopia patient pool and forecasted trends for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
In 2020, the total prevalent cases in the United States were 117,995,432 cases. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Gender-specific Cases of Presbyopia, Age-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Treated cases of Presbyopia] in the United States, from 2018 to 2030.
The United States Presbyopia Epidemiology
• The United States, in 2020, accounted for 101,657,603 diagnosed cases. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
• In the United States, the total gender-specific diagnosed cases of presbyopia were 40,663,041 for males and 60,994,562 for females in the year 2020.
• Based on secondary findings, presbyopia is more prevalent in females as compared to males.
Presbyopia Drug Chapters
The drug chapter segment of the presbyopia report encloses the detailed analysis of presbyopia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Presbyopia Emerging Drugs
AGN-190584 (Allergan (acquired by AbbVie))
AbbVie’s Allergan is developing, AGN-190584 an investigational optimized formulation of pilocarpine. It is a cholinergic muscarinic receptor agonist that is being investigated for treating symptoms associated with presbyopia as a topical, once-daily drop delivered by a proprietary vehicle.
The proposed mechanism of action of AGN-190584 is through dynamic pupil modulation, an effect in which the iris sphincter is contracted to achieve pupil size reduction in an optimal range. The goal of this pupil size reduction is to increase the depth of focus. Secondarily, it is believed to allow for increased accommodation through mild contraction of the ciliary muscle.
In October 2020, Allergan, an AbbVie company, announced the Phase III GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint.
MicroLine is Eyenovia’s patented pilocarpine presbyopia formulation. In ophthalmology, pilocarpine is a well-characterized drug, with several trials showing its ability to improve the depth of focus of the eye to reverse the age-related loss of accommodative effect and enhance close vision. The use of presbyopia pilocarpine as an eye drop may be limited because of the potential for side effects associated with the dosage, as well as the inconvenience and inconsistency of typical eyedropper dosing.
PresbiDrops (CSF-1) (Orasis Pharmaceuticals)
CSF-1 is a corrective eye DROP being developed for offering an alternative to reading glasses and intrusive surgical procedures to enhance the quality of life for people with presbyopia. Delivered directly to the eyes as a topical solution, CSF-1 provides a patented blend of current and well-studied ingredients with the potential for close vision restoration in people with presbyopia. CSF-1 is designed to be convenient and on-demand. Important increases in close vision and a superior safety profile have been seen in clinical trial reports to date, supporting possible improvements in the quality of life in people with presbyopia.
Note: Detailed emerging therapies assessment will be provided in the final report.
Presbyopia Market Outlook
Current clinical management of presbyopia includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants. The number of different techniques and the variety of approaches arises from the partial effectiveness of most methods to restore true accommodation. Presbyopia correction can be achieved with surgeries including Conductive keratoplasty, LASIK, LASEK, PRK, Presbylasik, etc., unilaterally as a monovision procedure or bilaterally.
Ultimately, the success of treatment depends on the lens power, the optical correction, the specific visual tasks, characteristics of the individual patient, and the appropriate patient education given by the practitioner. The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.
The Presbyopia market size in the United States is expected to change during the study period 2018–2030. The therapeutic market of Presbyopia in the United States is expected to increase during the study period (2018–2030) with a CAGR of 5.3%.
Presbyopia Pipeline Development Activities
The drugs which are in pipeline include:
1. AGN-190584 (Allergan (acquired by AbbVie))
2. MicroLine (Eyenovia)
3. PresbiDrops (CSF-1) (Orasis Pharmaceuticals)
Note: Detailed emerging therapies assessment will be provided in the final report.
• AGN-190584 (pilocarpine 1.25% ophthalmic solution) is expected to capture the maximum share among the emerging therapies owing to early mover advantage, dosing advantage, and visibility around the phase III results. The company has recently announced that Phase III GEMINI 1 and 2 studies met the primary endpoint, reaching statistical significance in improvement in near vision.
• The majority (~3/4th cases) of the presbyopia patients are using the eyeglasses for correction of close-up vision problems.
• Rising healthcare costs, shortage of trained ophthalmologists, and lack of accessibility of eye care services will be going to hit the market and this will impact the growth of the presbyopia market significantly.
• Growth of the presbyopia market is expected to be mainly driven by the rising prevalence of Presbyopia, upsurge in the launch of products with ready adoption, increasing lifestyle changes, and increase in the geriatric population.
Access and Reimbursement Scenario in Presbyopia Therapies
Currently, there are no approved therapies that reverse the normal aging process that causes presbyopia; instead, existing management focuses on either optical correction with medical devices (e.g., spectacles, contact lenses) or surgical intervention (e.g., a corneal inlay, corneal refractive procedures, and intraocular lens (IOL) replacement).
In 2005, the Centers for Medicare & Medicaid Services (CMS) published a ruling that reversed decades of policy. Previously, services were either covered or not, with no middle ground. Under the 2005 decision, Medicare would reimburse what it will cost to restore usable vision—in other words the charge for replacing the cataract lens with a traditional IOL, which was around USD 105—if a Medicare recipient needs a presbyopia-correcting intraocular lens (IOL), and the doctors will bill the patient for extra costs associated with the new lenses. Before the new ruling, the CMS said in a statement, Medicare rules “prevented beneficiaries from accessing these lenses.”
Note: Detailed HTA assessment will be provided in the final report.
To keep up with current market trends, we take KOLs and SME’s opinion working in the Presbyopia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Presbyopia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Presbyopia Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of Presbyopia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight has been provided into the Presbyopia epidemiology and treatment in the United States.
• Additionally, an all-inclusive account of both the current and emerging therapies for Presbyopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Presbyopia market; historical and forecasted is included in the report, covering drug outreach in the United States.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States Presbyopia market.
• In the coming years, the Presbyopia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Presbyopia. The launch of emerging therapies will significantly impact the Presbyopia market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Presbyopia.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Presbyopia Report Insights
• Patient Population
• Therapeutic Approaches
• Presbyopia Pipeline Analysis
• Presbyopia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Presbyopia Report Key Strengths
• 10 Years Forecast
• The United States Coverage
• Presbyopia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Presbyopia Report Assessment
• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• What was the Presbyopia Market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the Presbyopia total market size as well as market size by therapies in the United States during the study period (2018–2030)?
• What are the key findings pertaining to the market in the United States during the study period (2018–2030)?
• At what CAGR, the Presbyopia market is expected to grow in the United States during the study period (2018–2030)?
• What would be the Presbyopia market outlook in the United States during the study period (2018–2030)?
• What would be the Presbyopia market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• Presbyopia patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Presbyopia market?
• What are the disease risk, burdens, and unmet needs of Presbyopia?
• What is the historical Presbyopia patient pool in the United States?
• What would be the forecasted patient pool of Presbyopia in the United States?
• What will be the growth opportunities in the United States with respect to the patient population pertaining to Presbyopia?
• At what CAGR the population is expected to grow in the United States during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Presbyopia?
Current Treatment Scenario and Emerging Therapies:
• What are the current options for the treatment of Presbyopia?
• What are the current treatment guidelines for the treatment of Presbyopia in the US?
• How many companies are developing therapies for the treatment of Presbyopia?
• How many therapies are developed by each company for the treatment of Presbyopia?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Presbyopia?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Presbyopia and their status?
• What are the key designations that have been granted for the emerging therapies for Presbyopia?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Presbyopia market.
• To understand the future market competition in the Presbyopia market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Presbyopia in the US.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Presbyopia market.
• To understand the future market competition in the Presbyopia market.